Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1987 Jan;63(735):11–15. doi: 10.1136/pgmj.63.735.11

Failure of conventional chemotherapy in aggressive lymphomas.

D Cunningham 1, A Hepplestone 1, N L Gilchrist 1, J H Dagg 1, I L Evans 1, M Soukop 1
PMCID: PMC2428198  PMID: 2444960

Abstract

Between 1975 and 1982 in 2 centres in Glasgow, 53 previously untreated patients with aggressive non-Hodgkin's lymphomas received chemotherapy consisting of one of the following regimens-CVP, MOPP, CHOP or BACOP. Twenty nine patients (55%) entered complete remission (CR), 20 (38%) had partial remission (PR) and 4 (7%) had progressive disease (PD). Of the 29 patients in CR, 9 have relapsed and died, 5 died of infection, 4 died of non-malignant causes, and 11 (21%) remain alive and disease free. The median survival for the CR group is 40 months. All of the patients in the PR and PD group are dead, median survival 11 months. These chemotherapy regimens will cure only the minority of patients with aggressive lymphomas and the use of more intensive regimens is indicated.

Full text

PDF
11

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. DeVita V. T., Jr, Canellos G. P., Chabner B., Schein P., Hubbard S. P., Young R. C. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet. 1975 Feb 1;1(7901):248–250. doi: 10.1016/s0140-6736(75)91142-3. [DOI] [PubMed] [Google Scholar]
  2. Fisher R. I., DeVita V. T., Jr, Hubbard S. M., Longo D. L., Wesley R., Chabner B. A., Young R. C. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med. 1983 Mar;98(3):304–309. doi: 10.7326/0003-4819-98-3-304. [DOI] [PubMed] [Google Scholar]
  3. Gallagher C. J., Copplestone A., Meikle J. D., Lister T. A. The treatment of disseminated non-Hodgkin's lymphoma of unfavourable histology. Cancer Chemother Pharmacol. 1982;8(2):237–241. doi: 10.1007/BF00255490. [DOI] [PubMed] [Google Scholar]
  4. Jones S. E., Grozea P. N., Metz E. N., Haut A., Stephens R. L., Morrison F. S., Butler J. J., Byrne G. E., Jr, Moon T. E., Fisher R. Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study. Cancer. 1979 Feb;43(2):417–425. doi: 10.1002/1097-0142(197902)43:2<417::aid-cncr2820430203>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  5. Laurence J., Coleman M., Allen S. L., Silver R. T., Pasmantier M. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann Intern Med. 1982 Aug;97(2):190–195. doi: 10.7326/0003-4819-97-2-190. [DOI] [PubMed] [Google Scholar]
  6. Levine A. M., Forman S. J., Meyer P. R., Koehler S. C., Liebman H., Paganini-Hill A., Pockros A., Lukes R. J., Feinstein D. I. Successful therapy of convoluted T-lymphoblastic lymphoma in the adult. Blood. 1983 Jan;61(1):92–98. [PubMed] [Google Scholar]
  7. Lukes R. J., Collins R. D. Immunologic characterization of human malignant lymphomas. Cancer. 1974 Oct;34(4 Suppl):suppl–suppl:1503. doi: 10.1002/1097-0142(197410)34:8+<1488::aid-cncr2820340822>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  8. Skarin A. T., Canellos G. P., Rosenthal D. S., Case D. C., Jr, MacIntyre J. M., Pinkus G. S., Moloney W. C., Frei E., 3rd Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol. 1983 Feb;1(2):91–98. doi: 10.1200/JCO.1983.1.2.91. [DOI] [PubMed] [Google Scholar]
  9. Skarin A. T., Rosenthal D. S., Moloney W. C., Frei E., 3rd Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). Blood. 1977 May;49(5):759–770. [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES